Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed the question of whether NPM1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit. Patients and Methods Among 229 patients with NPM1m who were treated in the Acute Leukemia French Association 0702 (ALFA-0702) trial, MRD evaluation was available in 152 patients in first remission. Patients with nonfavorable AML according to the European LeukemiaNet (ELN) classification were eligible for ASCT in first remission. Results After induction therapy, patients who did not achieve a 4-log reduction in NPM1m peripheral blood-MRD (PB-MRD) had a higher cumulative incidence of relapse (subhazard ratio [SHR], 5.83; P < .001) and a shorter overall survival (OS; hazard ratio [HR], 10.99; P < .001). In multivariable analysis, an abnormal karyotype, the presence of FLT3-internal tandem duplication (ITD), and a < 4-log reduction in PB-MRD were significantly associated with a higher relapse incidence and shorter OS. In the subset of patients with FLT3-ITD, only age, white blood cell count, and < 4-log reduction in PB-MRD, but not FLT3-ITD allelic ratio, remained of significant prognostic value. In these patients with nonfavorable AML according to European LeukemiaNet, disease-free survival and OS were significantly improved by ASCT in those with a < 4-log reduction in PB-MRD. This benefit was not observed in those with a > 4-log reduction in PB-MRD, with a significant interaction between ASCT effect and PB-MRD response ( P = .024 and .027 for disease-free survival and OS, respectively). Conclusion Our study supports the strong prognostic significance of early NPM1m PB-MRD, independent of the cytogenetic and molecular context. Moreover, NPM1m PB-MRD may be used as a predictive factor for ASCT indication.

[1]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[2]  J. Bourhis,et al.  Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. , 2015, Blood.

[3]  D. Grimwade,et al.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Blood.

[4]  L. Bullinger,et al.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.

[5]  E. Hoster,et al.  Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse , 2014, Haematologica.

[6]  J. Cayuela,et al.  MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin , 2014, Oncotarget.

[7]  J. Cayuela,et al.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.

[8]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[9]  L. Bullinger,et al.  Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. , 2013, Blood.

[10]  O. Landt,et al.  The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. , 2013, Blood.

[11]  J. Cayuela,et al.  Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. , 2013, Blood.

[12]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[13]  H. Dombret,et al.  Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association , 2011, Leukemia.

[14]  K. Döhner,et al.  Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[16]  P. Brown,et al.  Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity , 2009, Hematological oncology.

[17]  A. Kohlmann,et al.  AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.

[18]  T. Haferlach,et al.  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. , 2009, Blood.

[19]  F. Lo‐Coco,et al.  Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[21]  M. Yao,et al.  Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations , 2007, Leukemia.

[22]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[23]  B. Falini,et al.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.

[24]  Bob Löwenberg,et al.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.

[25]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[26]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[27]  J. Cayuela,et al.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.

[28]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[29]  J. Cayuela,et al.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.

[30]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[31]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[32]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.

[33]  Nathan Mantel,et al.  Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .